Skip to main content
. 2022 Apr 20;30(7):2491–2504. doi: 10.1016/j.ymthe.2022.04.007

Figure 3.

Figure 3

APOL1 ASO improves glomerulosclerosis and fibrosis in NEFTA/G2APOL1 transgenic mice

(A) Representative PAS-stained kidney images of NEFTA/G2APOL1 mice treated with control ASO, APOL1 ASO1, or ASO2. Scale bars in upper panels, 20μm; lower panels, 10μm. (B) Semi-quantitative analysis of percent of tubular injury with cast, global glomerulosclerosis, and Sirius red positive area in each group; ∗p ≤ 0.05 versus control ASO-treated mice, ∗∗p ≤ 0.01 versus control ASO-treated mice. (C) Representative Sirius red-stained kidney images of NEFTA/G2APOL1 mice treated with control ASO, ASO1, or ASO2. Scale bars in upper panels, 20μm; lower panels, 10μm.